bms-986020
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01766817)
Timeline
Indications
Mechanism of action
- Lysophosphatidic acid receptor Edg-2ANTAGONIST
Lysophosphatidic acid receptor Edg-2 antagonist
- Lysophosphatidic acid receptor 1INHIBITOR
LPAR1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1noc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1- Mol. weight
- 482.54 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297270 ↗
Also known as
- bms-986020
- bms-986020
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02588625 | Phase 2 | Feb 1, 2016 | Bristol-Myers Squibb |
| NCT02227173 | Phase 1 | Sep 1, 2014 | Bristol-Myers Squibb, ICON |
| NCT02068053 | Phase 1 | Mar 1, 2014 | Bristol-Myers Squibb |
| NCT02101125 | Phase 1 | Mar 1, 2014 | Bristol-Myers Squibb |
| NCT02017730 | Phase 1 | Jan 1, 2014 | Bristol-Myers Squibb |
| NCT01766817 | Phase 2 | Jan 1, 2013 | Bristol-Myers Squibb |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 6 | 6 | 2 | 2013 |
| ICON | For profit | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1